“Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production”

What actually happened

Eli Lilly CEO Dave Ricks told CNBC in an interview timed to the groundbreaking of a new $6.5 billion Houston manufacturing plant that Foundayo, Lilly's oral GLP-1 pill, is capturing a growing share of new patients starting on GLP-1 pills. The company had made a similar disclosure a week earlier. The plant, expected operational by 2030, will produce Foundayo along with active ingredients for several other Lilly drug lines.

Key facts

• Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking the drugmaker's Foundayo, as the company tries to catch up to a lead in the space established by rival Novo.
• Corroborating this, Lilly separately disclosed a week prior that it had "captured more than 30% of new patients in the U.S. market for oral obesity treatments," narrowing Novo's early lead.
• Lilly said in August that it held about a 61% share in the overall market in the second quarter
• but that figure covers the whole GLP-1 market (injectables included), not the oral-pill segment the headline is about.
• The company said in August that the pill booked $98 million in sales for the second quarter, its first three-month period on the market.
• Novo's rival oral pill generated far more revenue in its own comparable early quarter, per BioSpace: "This falls well below the $355 million that Novo took home for the first quarter that oral Wegovy was available."

What to watch for

Watch Lilly's Q3 sales release for whether Foundayo's dollar revenue starts closing the gap with Novo's pill, not just its share of new-patient starts. Also watch whether Medicare's new obesity-drug coverage, which began in July, meaningfully shifts prescriber volume toward either pill in the next earnings cycle.